Table 2 Outcome measures in the (1–3)-β-d-glucan (BDG) and the control groups
Variable | BDG group (n = 53) | Control group (n = 55) | Between-group absolute difference in means (95% CI) | p value |
|---|---|---|---|---|
Primary outcome | ||||
Duration of antifungal therapy, days | 2 [1–3] | 10 [6–13] | 6.29 (3.94 to 8.65) | < 0.001 |
Secondary outcomes | ||||
30-day mortality, N (%) | 15 (28.3) | 15 (27.3) | − 1% (− 16.89 to 18.93) | 0.92 |
ICU mortality, N (%) | 16 (30.2) | 17 (30.9) | 0.7% (− 17.7 to 18.97) | 0.89 |
Hospital mortality, N (%) | 19 (35.9) | 18 (32.7) | − 3.2% (− 15.7 to 21.93) | 0.88 |
Subsequent ICI, N (%)* | 0 | 2 (3.6) | 3.6% (− 3.83 to 12.47) | 0.5 |
Hospital LOS, days | 35 [23.75–55.25] | 38 [20–59.5] | − 7.41 (− 21.55 to 6.73) | 0.87 |
ICU LOS, days | 18 [7.75–24.25] | 13 [7–26] | − 0.5 (− 6.95 to 5.95) | 0.23 |
Mechanical ventilation duration, days | 9 [4.75–17.25] | 9 [3.25–19.75] | 3.21 (− 2.05 to 8.46) | 0.97 |
Vasopressors duration, days | 4 [0.75–8.25] | 3 [0–11] | 0.06 (− 2.95 to 3.07) | 0.6 |
Total antifungals costs, € | 110 [2.64–708] | 113.2 [9.68–1255.6] | 318.63 (− 310.1 to 947.3) | 0.24 |
Echinocandins cost, € | 708 [185.6–1071.5] | 1320 [618.5–30,149.5] | 937.05 (− 64.2 to 1938.3) | 0.07 |
BG cost, € mean ± SD | 80.8 ± 20.4 | – | – | – |